Fabiana Vitiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fabiana Vitiello has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Fiorelli
Thoracic Surgery Unit University of Campania “Luigi Vanvitelli” Naples Italy
1 shared publication - Andrea Bianco
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy
1 shared publication - Cecilia Calabrese
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Azienda Ospedaliera di Rilievo Nazionale dei Colli, Monaldi Hospital, 80131 Naples, Italy
1 shared publication - Fabio Perrotta
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy
1 shared publication - Mariano Mollica
Pneumology Unit, Department of Translational Medicine, University of Campania ‘Luigi Vanvitelli’- Monaldi Hospital, Naples, Italy
1 shared publication - Marina Gilli
Oncology unit, Monaldi Hospital, Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 4 March 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1-4
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
Tracheobronchial malignant stenosis is a life-threatening condition which may cause recurrent infections due to lung atelectasis. Despite immunotherapy is less toxic than standard chemotherapy, recurrent lung infections may represent a challenge for this treatment. We report a clinical case of a patient with metastatic squamous cell carcinoma suffering from pulmonary infections due to central airway obstruction who underwent endoscopic recanalization followed by immunotherapy. A 64 year-old man was referred to our attention for the management of metastatic squamous cell carcinoma obstructing the right main bronchus with recurrent pulmonary infections. Patient exhibited strong positive PD-L1 expression (> 50%). Advanced disease stage contraindicated surgical treatment. Although therapy with immune check point inhibitors was indicated as first-line treatment, recurrent pulmonary infections made it unfeasible. Therefore, we planned a combined approach including endoscopic recanalization of central airway in order to resolve lung atelectasis, and lung infection followed by immunotherapy treatment with pembrolizumab in order to avoid local and systemic disease progression. At 16-week follow-up, the patient was alive in stable disease with improvement of clinical condition and no signs of lung infection.
- 4 March 2019
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 14 (1) , 1-4
Open AccessEndoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
Tracheobronchial malignant stenosis is a life-threatening condition which may cause recurrent infections due to lung atelectasis. Despite immunotherapy is less toxic than standard chemotherapy, recurrent lung infections may represent a challenge for this treatment. We report a clinical case of a patient with metastatic squamous cell carcinoma suffering from pulmonary infections due to central airway obstruction who underwent endoscopic recanalization followed by immunotherapy. A 64 year-old man was referred to our attention for the management of metastatic squamous cell carcinoma obstructing the right main bronchus with recurrent pulmonary infections. Patient exhibited strong positive PD-L1 expression (> 50%). Advanced disease stage contraindicated surgical treatment. Although therapy with immune check point inhibitors was indicated as first-line treatment, recurrent pulmonary infections made it unfeasible. Therefore, we planned a combined approach including endoscopic recanalization of central airway in order to resolve lung atelectasis, and lung infection followed by immunotherapy treatment with pembrolizumab in order to avoid local and systemic disease progression. At 16-week follow-up, the patient was alive in stable disease with improvement of clinical condition and no signs of lung infection.